Table 1.

Baseline Factor Analyses of CVF^a (Single- and All-Regimens Models)

Covariate	Single-Regimen Adjusted Incidence Rate Ratio (95% CI) [P Value], n = 1363		All-Regimens Adjusted Incidence Rate Ratio (95% CI) [P Value], n = 1431b
	Full Model	Final Model	Full Model	Final Model
RPV RAMs: yes/no	16.9 (3.74–76.1) [.0002]	21.7 (5.80–80.8) [<.0001]	11.3 (4.83–26.5) [<.0001]	10.4 (3.88–27.9) [<.0001]
HIV-1 subtype A6/A1: yes/no	24.5 (3.47–173) [.0013]	12.9 (4.42–37.5) [<.0001]	9.17 (0.984–85.3) [.0516]	9.15 (3.79–22.1) [<.0001]
Baseline BMI: kg/m2	1.09 (0.994–1.19) [.0671]	1.09 (1.00–1.19) [.0447]	1.09 (1.01–1.17) [.0205]	1.10 (1.02–1.18) [.0145]
Regimen: Q8W/Q4W	1.89 (0.536–6.67) [.3221]	d	1.90 (0.756–4.79) [.1719]	d
Integrase L74I:c yes/no	0.480 (0.068–3.40) [.4629]	d	1.23 (0.117–12.9) [.8642]	d
Sex at birth: female/male	0.796 (0.222–2.85) [.7254]	d	0.827 (0.329–2.08) [.6858]	d
Other NNRTI RAMs: yes/no	1.87 (0.465–7.51) [.3787]	d	2.65 (1.12–6.31) [.0273]	2.78 (1.15–6.76) [.0237]
CAB RAMs: yes/no	2.01 (0.115–35.0) [.6332]	d	1.66 (0.28–9.79) [.5742]	d
Other INSTI RAMs: yes/no	0 [.9998]	d	0.401 (0.022–7.28) [.5368]	d

Abbreviations: BMI, body mass index; CAB, cabotegravir; CI, confidence interval; CVF, confirmed virologic failure; IAS-USA, International Antiviral Society-USA; INSTI, integrase strand transfer inhibitor; LA, long-acting; NNRTI, nonnucleoside reverse transcriptase inhibitor; Q4W, every 4 weeks; Q8W, every 8 weeks; RAM, resistance-associated mutation; RPV, rilpivirine.

Bolded values represent statistically significant predictors (P < .05).

^aThrough week 124 for FLAIR, week 96 for ATLAS, and week 152 for ATLAS-2M.

^bParticipants who received both Q4W and Q8W CAB + RPV LA were included twice in the model, once for each regimen. A total of 1600 complete records was included.

^cL74I (including L74/L/I, but not any L74I mixtures containing M).

^dCovariates eliminated from the selected models. RAMs were determined per 2019 IAS-USA guidelines [25].